Q1 Earnings Estimate for BLFS Issued By HC Wainwright

BioLife Solutions, Inc. (NASDAQ:BLFS) – Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of BioLife Solutions in a research report issued to clients and investors on Thursday, July 23rd. HC Wainwright analyst Y. Chen expects that the medical equipment provider will earn $0.03 per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $31.00 price objective on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2027 earnings at $0.03 EPS, Q3 2027 earnings at $0.05 EPS and Q4 2027 earnings at $0.05 EPS.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.03. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. The company had revenue of $27.50 million during the quarter, compared to analyst estimates of $25.66 million.

BLFS has been the subject of several other reports. Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Saturday. Lake Street Capital cut shares of BioLife Solutions from a “buy” rating to a “hold” rating and cut their price objective for the stock from $33.00 to $31.00 in a research report on Wednesday. Zacks Research downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. TD Cowen lowered BioLife Solutions from a “buy” rating to a “hold” rating and lowered their target price for the stock from $33.00 to $31.00 in a research report on Wednesday. Finally, Craig Hallum cut BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 target price on the stock. in a report on Wednesday. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $31.43.

BioLife Solutions Stock Down 2.6%

Shares of NASDAQ BLFS opened at $29.98 on Friday. The firm has a market cap of $1.46 billion, a PE ratio of -374.70 and a beta of 1.94. BioLife Solutions has a 12-month low of $17.86 and a 12-month high of $32.23. The company’s fifty day simple moving average is $26.94 and its 200 day simple moving average is $23.55.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC purchased a new stake in shares of BioLife Solutions in the fourth quarter worth approximately $30,000. Kemnay Advisory Services Inc. purchased a new position in shares of BioLife Solutions during the fourth quarter valued at approximately $35,000. State of Wyoming purchased a new position in shares of BioLife Solutions during the first quarter valued at approximately $52,000. Quarry LP grew its holdings in BioLife Solutions by 50.9% during the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 713 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its holdings in shares of BioLife Solutions by 42.4% in the fourth quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 796 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

Insider Buying and Selling at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $23.70, for a total value of $15,405,000.00. Following the transaction, the insider owned 4,757,165 shares of the company’s stock, valued at approximately $112,744,810.50. This trade represents a 12.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have sold 1,200,000 shares of company stock valued at $28,125,000. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions News Summary

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: HC Wainwright reiterated a Neutral rating and a $31 price target while forecasting modest earnings growth for BioLife Solutions through 2027, which suggests analysts still see some upside from current levels. HC Wainwright earnings estimates and rating for BioLife Solutions
• Neutral Sentiment: Repligen’s planned acquisition of BioLife Solutions is being framed as strategically positive for Repligen’s cell therapy business, and the deal could provide a clear exit value for BLFS shareholders if completed. Zacks article on Repligen buying BioLife Solutions
• Negative Sentiment: Maxim Group downgraded BioLife Solutions (BLFS) from strong-buy to hold, adding pressure on the stock and signaling less enthusiasm from analysts. Maxim Group downgrade coverage via Zacks
• Negative Sentiment: Kahn Swick & Foti said it is investigating the adequacy of the price and process in BioLife’s proposed sale to Repligen, raising the risk of shareholder litigation or a challenged deal process. BusinessWire investor alert on BioLife Solutions sale investigation
• Negative Sentiment: TD Cowen also downgraded BioLife Solutions (BLFS) to hold, reinforcing the cautious tone around the stock after the acquisition announcement. TD Cowen downgrade on BioLife Solutions

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.